209 649

Cited 14 times in

Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma

Authors
Kim, SS  | Nam, JS | Cho, HJ  | Won, JH  | Kim, JW  | Ji, JH  | Yang, MJ  | Park, JH | Noh, CK  | Shin, SJ  | Lee, KM  | Cho, SW  | Cheong, JY
Citation
Journal of gastroenterology and hepatology, 32(1). : 199-207, 2017
Journal Title
Journal of gastroenterology and hepatology
ISSN
0815-93191440-1746
Abstract
BACKGROUND AND AIM: Circulating microRNA (miR)-122 has recently been investigated as a potential biomarker of various hepatic diseases, such as chronic hepatitis and hepatocellular carcinoma (HCC). We investigated the association between plasma miR-122 levels and the treatment outcomes following transarterial chemoembolization (TACE) in HCC patients.
METHODS: We included 177 HCC patients treated with TACE in the study: TACE refractoriness and liver transplantation-free survival were evaluated during follow up. Pretreatment plasma miR-122 levels were assessed using quantitative real-time polymerase chain reaction. Relative quantification of miR-122 expression (fold change) was determined using the 2((-DeltaDeltaCt)) method. MiR-16 was used as an internal control for the normalization of miRNA data.
RESULTS: During the mean follow up of 22.4 (range, 1-79) months, 112 (69.5%) patients exhibited TACE refractoriness. Multivariate analyses showed that tumor number (hazard ratio [HR], 2.51: 95% confidence interval [CI], 1.43-4.41: P = 0.001) and tumor size (HR, 2.65: 95% CI, 1.62-4.32: P = 0.000) can independently predict overall TACE refractoriness. High miR-122 expression (> 100) was associated with early TACE refractoriness (within 1 year: HR, 2.77: 95% CI, 1.12-6.86: P = 0.028), together with tumor number (HR, 22.73: 95% CI, 2.74-188.66: P = 0.004) and tumor size (HR, 4.90: 95% CI, 1.99-12.06: P = 0.001). Univariate analyses showed that high miR-122 expression tends to be associated with poor liver transplantation-free survival (HR, 1.42: 95% CI, 0.95-2.11: P = 0.085). However, it was statistically insignificant in multivariate analysis.
CONCLUSION: High expression levels of plasma miR-122 are associated with early TACE refractoriness in HCC patients treated with TACE.
MeSH

DOI
10.1111/jgh.13448
PMID
27194671
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Journal Papers > School of Medicine / Graduate School of Medicine > Radiology
Journal Papers > Research Organization > Genomic Instability Research Center
Ajou Authors
김, 순선  |  김, 진우  |  노, 충균  |  신, 성재  |  양, 민재  |  원, 제환  |  이, 기명  |  정, 재연  |  조, 성원  |  조, 효정  |  지, 재훈
Files in This Item:
27194671.pdfDownload
Export

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse